Cargando...
The impact of early phase price agreements on prices of orphan drugs
BACKGROUND: Innovative orphan drugs often have an incremental cost-effectiveness ratio (ICER) which is higher than the maximum threshold for reimbursement. Payers have limited budgets and often cannot pay the full price of a new product, but pharmaceutical and biotechnology companies require a minim...
Guardado en:
| Publicado en: | BMC Health Serv Res |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7953706/ https://ncbi.nlm.nih.gov/pubmed/33711994 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12913-021-06208-7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|